Substance Use

The Unique Benefit of MAT for Opioid Use Disorder

Medication-assisted treatment does something therapy alone can't: it addresses the brain changes that drive opioid cravings at a biological level. Here's what that means for you.

July 6, 20267 min readmatopioid use disordermedication-assisted treatment
Peter Scheid, MD

Medically reviewed by Peter Scheid, MD

Medical Director, SILC Health

Alexandra Truman, LMFT

Clinically reviewed by Alexandra Truman, LMFT

Clinical Director, Substance Use Services — SILC Health

Last reviewed: June 16, 2026

If someone you love is caught in the cycle of opioid use — or if that someone is you — you already know that willpower isn't the missing piece. You've probably tried stopping. Maybe more than once. And every time, the physical pull of withdrawal and the relentless grip of cravings made it feel impossible to get any traction. That experience is not a character flaw. It is biology. The most important thing MAT (medication-assisted treatment — using FDA-approved medications alongside counseling to treat opioid use disorder) does is something no amount of grit alone can replicate: it directly addresses the neurological changes that opioids leave behind in the brain, giving the rest of recovery a fighting chance to take root.

Why Opioid Use Disorder Is Different From 'Just Stopping'

Opioids — prescription painkillers, heroin, fentanyl — attach to opioid receptors (specialized docking sites in the brain that regulate pain, reward, and breathing) and over time reshape how those receptors work. NIDA (the National Institute on Drug Abuse, a federal research agency) has documented this process extensively: repeated opioid exposure dysregulates the brain's reward circuitry, produces physical dependence (a state where the body requires the drug to function normally), and dramatically lowers the brain's natural ability to generate dopamine (a chemical messenger tied to motivation and pleasure) on its own. The result is that stopping opioids cold doesn't just feel uncomfortable — it triggers an acute withdrawal syndrome (a predictable set of physical and psychological symptoms when opioid use stops abruptly) that can include severe pain, vomiting, insomnia, and overwhelming anxiety. Without medical support, most people return to use within days, not because they lack desire to stop, but because the body is demanding relief.

The Unique Benefit: Treating the Brain, Not Just the Behavior

Here is the core answer to the question this post is built around: the unique benefit of MAT for opioid use disorder is that it is the only treatment approach currently proven to directly stabilize the opioid-receptor system in the brain — reducing withdrawal, quieting cravings at a physiological level, and in the case of some medications, blocking the euphoric effect of opioids entirely. This is what SAMHSA (the Substance Abuse and Mental Health Services Administration, the federal agency overseeing addiction treatment policy) means when it calls MAT the 'gold standard' for opioid use disorder treatment. Behavioral therapies like CBT (cognitive behavioral therapy — identifying and changing thought patterns that drive use) and DBT (dialectical behavior therapy — building distress tolerance and emotional regulation skills) are powerful, but they work through insight and practice. MAT works through pharmacology. Together, they address the disorder from both directions: the brain and the mind.

The Three FDA-Approved Medications and How Each One Works

Not every medication works the same way or suits every person. One of the first conversations you'll have in a clinical assessment is about which option fits your history, your health, and your goals. Here is a plain-language breakdown of the three FDA-approved medications for opioid use disorder.

  1. Methadone — a full opioid agonist (a medication that activates opioid receptors fully, reducing cravings and withdrawal without producing a high at therapeutic doses). Methadone for OUD (opioid use disorder) is dispensed through federally certified opioid treatment programs (OTPs — specialized clinics licensed to provide methadone daily). It has decades of clinical evidence behind it and remains one of the most studied substances in addiction medicine. Because it is long-acting, it prevents the peaks and valleys of shorter-acting opioids that reinforce the cycle of craving and use.
  2. Buprenorphine — a partial opioid agonist (a medication that activates opioid receptors partially, enough to reduce withdrawal and cravings but with a ceiling effect that limits misuse risk). Buprenorphine is often combined with naloxone (an opioid-blocker that discourages injection misuse) in formulations like Suboxone. It can be prescribed in an office-based setting by a certified physician, nurse practitioner, or physician assistant, making it more accessible than methadone. The combination's ceiling effect is a meaningful safety advantage for many patients.
  3. Naltrexone — an opioid antagonist (a medication that fully blocks opioid receptors, preventing any opioid from producing a high). Unlike methadone and buprenorphine, naltrexone is non-opioid and non-addictive, which makes it well-suited for patients who have already completed detox and prefer a medication with no opioid activity. Extended-release injectable naltrexone (brand name Vivitrol) removes the daily adherence challenge of a pill and provides month-long receptor blockade.

What MAT Makes Possible That Nothing Else Can

Think of it this way: trying to do the emotional and behavioral work of recovery while your brain is in active withdrawal is like trying to learn to swim while you're drowning. MAT stabilizes the water. When cravings are quieted and withdrawal is managed, a person can actually show up to therapy. They can sleep. They can hold a job or rebuild a relationship or start to believe that a different life is possible. This is not a metaphor — it is a measurable clinical reality. Research published in NEJM and cited by NIDA consistently shows that patients on MAT have higher treatment retention rates (the percentage who stay in care long enough to benefit), lower rates of illicit opioid use, reduced risk of overdose death, and lower rates of infectious disease transmission. Every one of those outcomes starts with the brain being stable enough to let a person engage.

MAT Is Not 'Trading One Drug for Another'

This is one of the most common and painful misconceptions people hear — often from people they love and trust. Someone who cares about you might say it. It's worth addressing directly. The notion that MAT is just substituting one addiction for another reflects a misunderstanding of what opioid use disorder actually is. ASAM (the American Society of Addiction Medicine, the national body that sets clinical standards for addiction treatment) defines opioid use disorder as a chronic brain disease, not a matter of choice or moral failing. Using an FDA-approved medication to treat a brain disease is no different from using insulin to treat diabetes or an ACE inhibitor to treat heart disease. The goal of MAT is not to keep someone dependent on a substance indefinitely — though for some people long-term maintenance is the safest, most effective path — but to stabilize brain chemistry so that recovery becomes livable. Duration is a clinical decision, not a judgment.

MAT Works Best Inside a Full Continuum of Care

MAT is a cornerstone, but recovery is built on more than one stone. ASAM's levels of care (a national clinical scale that matches treatment intensity to need, from medically managed detox through outpatient follow-up) provide a framework for understanding how MAT fits into a larger plan. At the highest-intensity end, someone in acute opioid withdrawal may need medically managed detox (24-hour clinical supervision during the withdrawal phase) before MAT can begin. Programs like Cove Detox, Leucadia Detox, Harbor Detox, and Seaside Detox provide that kind of structured, safe medical environment for the first hours and days. Once stable, the path typically moves through residential treatment (immersive 24-hour structured programming), PHP (partial hospitalization program — intensive day treatment, usually five or more hours per day), IOP (intensive outpatient program — structured group and individual therapy, typically three days or more per week), and eventually standard outpatient care. At Southern California Recovery Centers and Riverfront Recovery, MAT is woven into these levels rather than siloed off — because medication without counseling leaves gaps, and counseling without medication often leaves people too physically destabilized to absorb it. One Path Mental Health supports the psychiatric side of co-occurring conditions (mental health disorders that exist alongside addiction) that frequently travel with opioid use disorder, like depression, PTSD, and anxiety.

Who Is a Good Candidate for MAT?

Most people with moderate to severe opioid use disorder are candidates for some form of MAT, but the right medication depends on several factors a clinical team will assess. ASAM and SAMHSA both recommend that MAT be offered broadly and early — there is no prerequisite number of failed attempts or required period of suffering before it's appropriate. A clinician will look at the duration and severity of opioid use, prior treatment history, co-occurring medical and mental health conditions, pregnancy status, living situation, and personal preference. If you've been told you have to 'want it badly enough' before medication is on the table, that's a provider philosophy that runs contrary to the evidence. You deserve a clinical conversation, not a gatekeeping test of your motivation.

  • People with moderate to severe opioid use disorder who have experienced repeated withdrawal or relapse cycles
  • Individuals for whom opioid withdrawal poses medical risk (including those with cardiac conditions, severe anxiety, or co-occurring mental health conditions)
  • Pregnant people — buprenorphine and methadone have established safety profiles in pregnancy and are recommended by ACOG (the American College of Obstetricians and Gynecologists)
  • Anyone who has previously experienced a non-fatal overdose, given the dramatically elevated risk of fatal overdose in the period immediately following detox without MAT
  • People who have expressed preference for medication support — patient preference is itself a clinical factor in ASAM's decision-making framework

We're Here If You Want to Talk About What This Could Look Like for You

We know that reading about MAT and actually taking a step toward it are two very different things. If you're at the reading stage, that's enough for right now. But if you're ready to hear what options actually exist — for yourself or someone you care about — our team at SILC Health is available at (844) 422-8640, any time. There's no intake questionnaire on that first call, no commitment required, and no one is going to pressure you toward a specific program. We'll listen to where you are, answer your questions honestly, help you understand your insurance coverage, and walk you through what the process would actually look like. You can bring a family member or friend on the call if that makes it feel safer. The call is the smallest possible step, and we believe in small steps.

How to Get Started: The Practical Path Forward

If you're ready to move from information to action, here is what the process typically looks like when you reach out to SILC Health. First, a real person answers the phone at (844) 422-8640 — not a voicemail box. Second, they ask about your situation and what you're looking for, not to screen you out but to understand what kind of help actually fits. Third, if insurance verification is something you want help with, they can walk you through that during the call or connect you to our admissions team who can do it on your behalf. Fourth, if your situation calls for medically supervised detox first, we can discuss what that environment looks like and what happens after. Fifth, within the same call or a follow-up, you'll have a clearer picture of what level of care makes sense, what MAT options are available in your situation, and what the realistic next 72 hours could look like. Recovery doesn't start with a perfect plan. It starts with one honest conversation.

People also ask

Common questions.

What is the unique benefit of MAT compared to therapy alone for opioid use disorder?

The most unique thing MAT does is address opioid use disorder at the neurological level — stabilizing the opioid-receptor system in the brain that chronic opioid use has disrupted. Therapy works through insight and behavior change; MAT works through pharmacology, reducing withdrawal and cravings at a biological level so that therapy can actually be absorbed. SAMHSA calls this combination the gold standard because neither approach alone addresses the full picture of what opioid use disorder is.

Is MAT just replacing one addiction with another?

This is one of the most common concerns people have, and it's worth taking seriously rather than dismissing. ASAM defines opioid use disorder as a chronic brain disease, and using FDA-approved medication to treat a brain disease is medically equivalent to treating any other chronic condition with prescribed medication. When MAT is used as intended, the goal is clinical stabilization — not perpetuating a cycle of compulsive use. For some people, long-term maintenance is the safest path; for others, medication is a bridge to a point where tapering becomes appropriate. That's a clinical conversation, not a moral one.

How long does someone typically stay on MAT for opioid use disorder?

There's no universal answer, and anyone who gives you a fixed timeline without knowing your clinical history is guessing. ASAM and SAMHSA both recommend that duration of MAT be individualized based on clinical need, not arbitrary time limits. Research consistently shows that longer durations of MAT are associated with better outcomes, and stopping medication prematurely is one of the leading contributors to relapse and overdose risk. Your care team will work with you on what the right duration looks like for you.

Can MAT be used during pregnancy?

Yes — and for pregnant people with opioid use disorder, MAT is strongly recommended. Both methadone and buprenorphine have established safety profiles in pregnancy and are endorsed by ACOG (the American College of Obstetricians and Gynecologists). Untreated opioid use disorder during pregnancy carries significant risks to both the parent and the fetus; MAT reduces those risks substantially. If you're pregnant and navigating opioid use disorder, please reach out to us at (844) 422-8640 — we want to help you find appropriate care as quickly as possible.

Will my insurance cover MAT for opioid use disorder?

Most insurance plans — including Medicaid, Medicare, and the majority of private plans — are required under the ACA (the Affordable Care Act, the federal law mandating mental health and substance use coverage parity) to cover substance use disorder treatment including MAT. Coverage specifics vary by plan, and our admissions team can help you verify your benefits at no cost during your first call. Call (844) 422-8640 and we'll walk you through it together.

Does MAT mean I have to go to a clinic every day?

It depends on which medication and which setting you're in. Methadone for opioid use disorder is typically dispensed daily at a federally certified opioid treatment program, at least initially, though many programs allow take-home doses as treatment progresses. Buprenorphine-based medications like Suboxone can be prescribed in an office-based setting and filled at a pharmacy, more like a standard prescription. Extended-release injectable naltrexone (Vivitrol) is given once a month in a clinical setting. The right fit depends on your lifestyle, your situation, and your clinical picture — something worth discussing in a real conversation.

What happens if I've already tried MAT and relapsed?

A relapse while on MAT — or after stopping it — doesn't mean MAT doesn't work for you. It means something in the treatment plan needs to be adjusted, whether that's the medication, the dose, the level of counseling support, or the life circumstances surrounding treatment. NIDA's research on opioid use disorder emphasizes that relapse rates for chronic conditions like this are comparable to other chronic diseases like hypertension and diabetes, and they respond the same way: by returning to or adjusting treatment, not by abandoning it. If you've been through this before and you're not sure where to turn, call us at (844) 422-8640. We've had this conversation before, and we won't make you feel judged for having it again.

Talk to admissions

Ready when you are.

One call confirms benefits, walks through what arrival looks like, and sets a clear plan from wherever you're starting.

(844) 422-8640